<DOC>
	<DOCNO>NCT00001080</DOCNO>
	<brief_summary>To ascertain whether origin plasma HIV-1-RNA follow T cell activation represent activation latently infect cell increase cell permissive replace viral mutant . The mechanism immune stimulation increase circulate level HIV-1 known . In particular , uncertain whether transient increase plasma HIV-1 RNA due enhance replication actively replicate pool HIV-1 , due instead activation proviral sequence previously rest CD4+ cell . One approach discriminate alternative `` molecular pulse-chase '' experiment . In approach , drug resistant mutant would select administration Lamivudine ( 3TC ) .</brief_summary>
	<brief_title>Effect Vaccination Turnover Lamivudine ( 3TC ) Sensitive Resistant Virus Populations HIV-1-Infected Individuals</brief_title>
	<detailed_description>The mechanism immune stimulation increase circulate level HIV-1 known . In particular , uncertain whether transient increase plasma HIV-1 RNA due enhance replication actively replicate pool HIV-1 , due instead activation proviral sequence previously rest CD4+ cell . One approach discriminate alternative `` molecular pulse-chase '' experiment . In approach , drug resistant mutant would select administration Lamivudine ( 3TC ) . Twenty subject without prior 3TC experience treat 3TC 2 week . On day 14 , half subject receive immunization influenza pneumococcal vaccine . 3TC discontinued time . Patients follow 4 week immunization .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral therapy , provide patient dose drug 60 day prior study entry . Patients must : Documented HIV infection . CD4 lymphocyte count &gt; 300 cells/mm3 . One plasma HIV1 RNA level &gt; = 20,000 &lt; 120,000 copies/ml . Prior Medication : Allowed : Stable antiretroviral therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Presence AIDS define opportunistic infection , include Kaposi 's sarcoma . Allergy influenza pneumococcal vaccine component ; egg egg product . Unexplained temperature &gt; = 38.5 degree C 7 consecutive day within 30 day prior study entry . Concurrent participation experimental therapy . Concurrent Medication : Excluded : Systemic chemotherapy . Steroids . Corticosteroids . Vaccinations . Any new antiretroviral agent patient take time study entry prescribe study . Colony stimulate factor include GCSF rEPO . Immune modulators/immune base therapy . Concurrent Treatment : Excluded : Radiation therapy . Transfusion dependent patient . Patients follow prior condition exclude : History AIDS defining opportunistic infection , include Kaposi 's sarcoma ( except limit cutaneous disease [ &lt; 5 lesion ] ) . History acute chronic pancreatitis . Prior Medication : Excluded : Prior treatment 3TC . Excluded within 30 day study entry : Treatment immune modulators . Acute chronic therapy recognize infection ( eg , influenza , HSV , VZV ) . Excluded within 1 year study entry : Treatment influenza and/or pneumonia vaccine [ AS PER AMENDMENT 1/23/97 : influenza vaccine ] . [ AS PER AMENDMENT 1/23/97 : Excluded within 3 year study entry : Pneumonia vaccine . ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Lymphocyte Transformation</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Drug Resistance , Microbial</keyword>
	<keyword>CD4-Positive T-Lymphocytes</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Influenza Vaccine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Bacterial Vaccines</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Pneumonia , Pneumococcal</keyword>
	<keyword>Viral Load</keyword>
</DOC>